NA
DNA icon

NewEdge Advisors’s Ginkgo Bioworks DNA Stock Holding History

NewEdge Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-618
Closed -$8.26K – 3846
2024
Q2 		$8.26K Sell
618
-21
-3% -$627 ﹤0.01% 2930
2024
Q1 		$29.7K Buy
639
+242
+61% +$12.5K ﹤0.01% 2484
2023
Q4 		$20.3K Buy
397
+389
+4,863% +$23.8K ﹤0.01% 2570
2023
Q3 		$543 Hold
8
– – ﹤0.01% 3243
2023
Q2 		$558 Sell
8
-587
-99% -$34.7K ﹤0.01% 3307
2023
Q1 		$31.6K Buy
595
+198
+50% +$12.5K ﹤0.01% 2183
2022
Q4 		$7.58K Buy
+397
New +$36.5K ﹤0.01% 2458

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

NewEdge Advisors's DNA Position: Q3 2024 in Review

NewEdge Advisors sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 618 shares — an estimated $8.26K sold.

NewEdge Advisors first reported a position in DNA in Q4 2022 and held it in 7 quarters. The position peaked at $31.6K in Q1 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • NewEdge Advisors reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • NewEdge Advisors sold 618 Ginkgo Bioworks shares in Q3 2024, an estimated $8.26K.
  • NewEdge Advisors first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 7 quarters.
  • NewEdge Advisors's Ginkgo Bioworks position peaked at $31.6K in Q1 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on NewEdge Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.